With EGFR being the most relevant in the context of metastatic disease, the review will focus on the description of clinically pertinent mutations occurring within this tyrosine kinase receptor and the current and novel therapeutic approaches developed to date. The gene discussed is EGFR; the disease is metastatic neoplasm.